Eli Lilly will acquire SiteOne and with it STC 004 a pain therapy candidate

Lilly has agreed to acquire privately held SiteOne and its Phase II-ready Nav1.8 inhibitor for pain for up to $1 billion .Lilly is looking to complement its internal pipeline for pain with a buyout of privately held SiteOne Therapeutics, which will bring with it Phase II-ready STC-004, a pain therapy candidate from the same non-opioid drug class as Vertex’s recently approved Journavx (suzetrigine). While STC-004 and Journavx are sodium channel Nav1.8 inhibitors, SiteOne also has partnered since 2022 with Vertex to study the potential of Nav1.7 inhibitors in pain and neuronal hyperexcitability disorders.